Alnylam plunges as earnings deliver ‘one-two punch’

Thursday, July 30, 2026Ben Fidler and Jacob BellView original

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Read the full article on the original site.